Brind.

Morgan Stanley Boosts Tempus AI Revenue Outlook Following Reimbursement Clarity

2 reports, 2 independent Updated Sep 18
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Tempus AI secured AstraZeneca as a customer. Morgan Stanley reframed Tempus AI's revenue story, citing newly clarified reimbursement pricing for its AI-powered diagnostics. The investment bank estimated that Tempus AI's xT pricing could add $80 million to $100 million next year, and xF approval could add $250 million to $300 million annually.

From 247wallst.com

Why it matters

Some supportBrind's analysis of the reports

Morgan Stanley's analysis positively influenced Tempus AI's revenue outlook and potential revenue streams. This clarity on reimbursement pricing led to a significant rally in Tempus AI's shares.

From 247wallst.com

Who's involved

  • TempusBiotechnology company providing AI-driven diagnostics and securing customer partnerships.
  • AstraZenecaPharmaceutical company partnering with Tempus AI on oncology foundation model development.
  • Morgan StanleyInvestment bank providing financial ratings and analysis to Tempus AI and AstraZeneca.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • TempusSpeculative

    Tempus AI's revenue could increase due to clarified reimbursement pricing and new customer deals.

  • AstraZenecaSpeculative

    AstraZeneca might see increased data licensing revenue from its partnership with Tempus AI.

How it developed

Newest first. Tap a step to see who reported it.
  1. Potential reimbursement revenue for AI diagnostics testing was flagged, alongside market reactions to the FED rate hike.1 source
  2. Tempus AI secures AstraZeneca as a customer and receives a revenue outlook boost from Morgan Stanley.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped